ArticleCurrent medicinal chemistry2026
Exploring the Toxicological Impact and Mechanisms of DEHP Exposure on Prostate Cancer Through Network Toxicology and Machine Learning Algorithms.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate Cancer (PCa) is the most common male malignancy, and its initiation and progression may be influenced by environmental pollutants such as di(2-ethylhexyl) phthalate (DEHP).
methodsPotential targets of DEHP were retrieved from ChEMBL, SwissTargetPrediction, and PharmMapper databases. DEHP-related genes correlated with PCa were identified by intersecting the DEHP target gene set with PCa-associated genes. Machine learning approaches were employed to identify and characterize the core genes linked to PCa. SHapley Additive exPlanations (SHAP) analysis was used to evaluate model interpretability. Molecular docking was performed to assess the binding interactions between DEHP and the key target proteins. Cellular validation was performed using CCK-8 assay, quantitative reverse transcription PCR (RT-qPCR), and western blot analysis.
resultsA total of 53 genes were identified as potential actionable targets of DEHP in PCa pathobiology. Through machine learning, these genes were reduced to 12 genes (ACACB, CD200, FERMT2, GCNT1, GNAI2, GSTM2, IMPDH2, ITGA2, MMP26, PMM2, PRKCA, and SRD5A2), which exhibited distinct dysregulation patterns in PCa tissues. Furthermore, molecular simulation docking simulations demonstrated its robust binding interactions with key targets, including PMM2, ITGA2, GSTM2, IMPDH2, and PRKCA, warranting further experimental validation. DISCUSSION: DEHP, an industrial chemical, may contribute to PCa via multiple pathways. A 12-gene model for DEHP-associated PCa was identified, among which PMM2 may play a key role in mediating oncogenic effects via metabolic, redox, and signaling reprogramming.
conclusionsThe findings indicated that DEHP can influence the development of PCarelated pathways through targeting specific genes and signaling, exhibiting the potential to serve as a biomarker to assess the risk of PCa related to DEHP exposure.
Indexed as
Identifiers
42304923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.